Completed OBSERVATIONAL NCT06935942
The Associations of Plasminogen Activator Inhibitor-1 Gene Polymorphisms With Crohn's Disease in Chinese Patients
Sponsor: Second Affiliated Hospital of Wenzhou Medical University
Conditions
Crohn Disease
Interventions
Ustekinumab - Standard Dosage
Updated 1 time since 2025 Last updated: Apr 18, 2025 Started: Jan 1, 2020 Primary completion: Jan 1, 2025 Completion: Jan 1, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06935942, this observational or N/A phase trial focuses on Crohn Disease and remains completed. Sponsored by Second Affiliated Hospital of Wenzhou Medical University, it has been updated 1 time since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Completed
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Second Affiliated Hospital of Wenzhou Medical University
Data source: Second Affiliated Hospital of Wenzhou Medical University
For direct contact, visit the study record on ClinicalTrials.gov .